Ensituximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	MUC5AC
Clinical data
ATC code	none
Identifiers
CAS Number	1092658-06-4^N
ChemSpider	none
UNII	F988K568V2
KEGG	D09898^N
Chemical and physical data
Formula	C₆₃₄₂H₉₈₀₀N₁₆₇₈O₁₉₈₅S₄₆
Molar mass	142788.68 g·mol⁻¹
^NY (what is this?) (verify)

Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers.^[1] The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers.^[2] The target might be Mucin 5AC.^[3]

The antibody was discovered by scientists at Neogenix Oncology using tumor antigens that had been identified years earlier by Ariel Hollinshead; the founder of Neogenix had founded a prior company based on Hollinshead's work as well.^[4] Neogenix worked with Selexis to develop the CHO cell line expressing ensituximab^[5]^[6] and also worked with Goodwin Biotechnology Inc on process development.^[7]

Ensituximab was granted orphan drug designation for pancreatic cancer by the FDA in 2010.^[8]

In 2011 Neogenix was forced to declare bankruptcy because the SEC opened an investigation into its use of unregistered broker-dealers in the course of raising $30M, and it could not raise further funds; in 2012 Neogenix sold its assets to a group of its investors who had formed a company called Precision Biologics.^[9]

In 2016, Precision released data from a Phase II trial colorectal cancer and at that time was working with Cytovance Biologics as its contract manufacturing organization.^[10]

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
^ "Ensituximab". NCI Drug Dictionary. Retrieved 31 January 2017.
^ Kim RD, Azad NS, Morse MA, Poplin E, Mahipal A, Tan B, et al. (2020). "Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer". Clinical Cancer Research. 26 (14): 3557–3564. doi:10.1158/1078-0432.CCR-20-0426. ISSN 1078-0432. PMID 32303539. S2CID 215809528.
^ Morrison T (July 11, 2007). "Neogenix Uses Cancer Vaccine And Antibody Approaches". BioWorld Today.
^ Neogenix Oncology, Inc. - Pharmaceuticals & healthcare - Deals and alliances profile. (2015). London: Global Data Ltd.
^ "Press ReleaseL Selexis and Neogenix Oncology Execute Commercial License Agreement - Selexis SA". Selexis SA. 5 January 2011.
^ "From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics". Frost & Sullivan. 14 September 2007.
^ Staff (1 December 2010). "FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)". Formulary Journal. Archived from the original on 2 February 2017. Retrieved 31 January 2017.
^ Davie AJ (5 October 2012). "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 1: How It All Happened". Strictly Business.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 2: What Neogenix Did". Strictly Business. 24 October 2012.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 3: When the Genie Can't Be Put Back in the Bottle". Strictly Business. 17 November 2012.
^ "Ensituximab - Precision Biologics". Adis Insight. Springer Nature Switzerland AG. Retrieved 30 January 2017.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab
Humanized	Abituzumab^§ Alemtuzumab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III